Gastroesophageal Reflux Disease Market in the US to Show Promising Growth at a CAGR of 6% During the Forecast Period (2025-2034) | DelveInsight
The gastroesophageal reflux disease market continues to be constrained by a limited number of approved treatment options and persistent unmet needs, particularly among patients who do not achieve adequate control with PPIs. Nevertheless, advancements in diagnostic approaches and the introduction of next-generation therapies, such as BLI5100 (Braintree Laboratories), linaprazan glurate (Cinclus Pharma), and others, are expected to sustain market growth from 2025 to 2034.
LAS VEGAS, Jan. 22, 2026 /PRNewswire/ -- DelveInsight's Gastroesophageal Reflux Disease Market Insights report includes a comprehensive understanding of current treatment practices, gastroesophageal reflux disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Gastroesophageal Reflux Disease Market Summary
Discover GERD market size by revenue and patient population @ https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Gastroesophageal Reflux Disease Market
Gastroesophageal Reflux Disease Market Analysis
Gastroesophageal Reflux Disease Competitive Landscape
BLI5100 (tegoprazan) from Braintree Laboratories (Sebela Pharmaceuticals) and linaprazan glurate from Cinclus Pharma are in late-stage development and are expected to compete with VOQUEZNA by providing additional options for patients who remain inadequately controlled on standard PPI therapy.
Braintree Laboratories' BLI5100 (tegoprazan) is a next-generation potassium-competitive acid blocker (P-CAB) to treat acid-related gastrointestinal disorders. Administered orally, it achieves rapid and durable suppression of gastric acid by directly blocking the proton pump within parietal cells, through a mechanism independent of H⁺/K⁺-ATPase activation that characterizes proton pump inhibitors (PPIs). Its molecular architecture allows interaction nearer the luminal surface of the pump, supporting a faster onset of action compared with conventional PPIs and potentially other P-CABs. BLI5100 is currently under evaluation in two Phase III clinical studies in the United States for erosive esophagitis and non-erosive reflux disease (NERD).
Cinclus Pharma's Linaprazan glurate is also a next-generation P-CAB and serves as the prodrug of linaprazan, originally discovered by AstraZeneca. It features a differentiated mechanism of action, enhanced pharmacokinetic properties, and the potential for improved therapeutic effectiveness. Clinical data indicate greater gastric acid suppression than that achieved with existing treatment options. The agent is being advanced for patients with moderate-to-severe erosive GERD and Helicobacter pylori infection who have an inadequate response to currently available therapies.
The anticipated launch of these emerging therapies are poised to transform the gastroesophageal reflux disease market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the gastroesophageal reflux disease market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the latest drugs and therapies for GERD @ Gastroesophageal Reflux Disease Drugs Market
Recent Developments in the Gastroesophageal Reflux Disease Market
What is Gastroesophageal Reflux Disease?
Gastroesophageal reflux disease (GERD) is a chronic digestive disorder in which stomach acid and, at times, bile flow back into the esophagus, the tube that connects the mouth to the stomach. This backflow, known as acid reflux, occurs when the lower esophageal sphincter (LES), a ring of muscle at the junction of the esophagus and stomach, becomes weak or relaxes inappropriately. Repeated exposure of the esophagus to stomach acid can irritate and damage its lining, leading to symptoms such as persistent heartburn, acid regurgitation, chest discomfort, difficulty swallowing, and chronic cough. If left untreated, GERD can result in complications including esophagitis, strictures, Barrett's esophagus, and an increased risk of esophageal cancer.
Gastroesophageal Reflux Disease Epidemiology Segmentation
The gastroesophageal reflux disease epidemiology section provides insights into the historical and current gastroesophageal reflux disease patient pool and forecasted trends for the leading markets. In 2024, NERD accounted for the majority of GERD cases in the United States, with approximately 23 million cases, while erosive esophagitis represented a smaller share at around 10 million cases.
The gastroesophageal reflux disease treatment market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:
Gastroesophageal Reflux Disease Market Forecast Report Metrics
Details
Study Period
2020–2034
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Gastroesophageal Reflux Disease Market CAGR (US)
6 %
Gastroesophageal Reflux Disease Market Size in 2024 (US)
USD 3.3 Billion
Key Gastroesophageal Reflux Disease Companies
Braintree Laboratories, Cinclus Pharma, Phathom Pharmaceuticals, Takeda, and others
Key Gastroesophageal Reflux Disease Therapies
BLI5100 (Tegoprazan), Linaprazan glurate, VOQUEZNA, and others
Scope of the Gastroesophageal Reflux Disease Market Report
Download the report to understand what will drive the GERD market in the next decade @ Gastroesophageal Reflux Disease Market Forecast
Table of Contents
1
Gastroesophageal Reflux Disease Market Key Insights
2
Gastroesophageal Reflux Disease Market Report Introduction
3
GERD Market Overview at a Glance
3.1
Market Share (%) Distribution of GERD by Therapies in 2024 in the 7MM
3.2
Market Share (%) Distribution of GERD by Therapies in 2034 in the 7MM
4
Epidemiology and Market Methodology
5
Executive Summary
6
Key Events
7
Disease Background and Overview
7.1
Introduction
7.2
Signs and Symptoms
7.3
Causes
7.4
Risk Factors
7.5
Prognosis
7.6
Pathophysiology
7.7
Complications
7.8
Diagnosis
8
GERD Treatment and Management
8.1
Lifestyle Modifications
8.2
Pharmacological Therapy
8.3
Endoscopic and Surgical Therapy
8.4
Treatment Guidelines
8.5
Treatment Algorithm
9
GERD Patient Journey
10
Epidemiology and Patient Population
10.1
Key Findings
10.2
Assumptions and Rationale
10.3
Total Diagnosed Prevalent Cases of GERD in the 7MM
10.4
The United States
10.4.1
Prevalent Cases of GERD in the United States
10.4.2
Diagnosed Prevalent Cases of GERD in the United States
10.4.3
Gender-specific Cases of GERD in the United States
10.4.4
Age-specific Cases of GERD in the United States
10.4.5
Type Specific Cases of GERD in the United States
10.4.6
Grade-specific Cases of GERD (erosive esophagitis) in the United States
10.4.7
Total Treated Cases of GERD in the United States
10.5
EU4 and the UK
10.6
Japan
11
Marketed GERD Therapies
11.1
VOQUEZNA (Vonoprazan): Phathom Pharmaceuticals/Takeda
11.1.1
Product Description
11.1.2
Regulatory Milestones
11.1.3
Other Developmental Activities
11.1.4
Summary of Pivotal Trials
11.1.5
Clinical Developmental Activities
11.1.5.1
Clinical Trials Information
11.1.6
Safety and Efficacy
11.1.7
Analyst Views
12
Emerging GERD Therapies
12.1
Key Cross Competition
12.2
BLI5100 (Tegoprazan): Braintree Laboratories
12.2.1
Product Description
12.2.2
Other Developmental Activities
12.2.3
Clinical Developmental Activities
12.2.3.1
Clinical trial information
12.2.4
Safety and Efficacy
12.2.5
Analyst View
12.3
Linaprazan Glurate: Cinclus Pharma
13
GERD Market: Seven Major Market Analysis
13.1
Key Findings
13.2
Key GERD Market Forecast Assumptions
13.3
Gastroesophageal Reflux Disease Market Outlook
13.4
Conjoint Analysis
13.5
Total Market Size of GERD in the 7MM
13.6
Market Size of GERD by Therapies in the 7MM
13.7
GERD Market Size in the United States
13.7.1
Total Market Size of GERD in the United States
13.7.2
Market Size of GERD by Therapies in the United States
13.8
GERD Market Size in EU4 and the UK
13.9
GERD Market Size in Japan
14
KOL Views on GERD
15
GERD Market SWOT Analysis
16
GERD Market Unmet Needs
17
Gastroesophageal Reflux Disease Market Access and Reimbursement
17.1
The United States
17.2
EU4 and the UK
17.3
Japan
17.4
Reimbursement Scenario in GERD
18
Bibliography
19
GERD Market Report Methodology
Related Reports
Gastroesophageal Reflux Disease Clinical Trial Analysis
Gastroesophageal Reflux Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GERD companies, including Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, among others.
Gastroparesis Market
Gastroparesis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key gastroparesis companies, including Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, among others.
Eosinophilic Esophagitis Market
Eosinophilic Esophagitis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key eosinophilic esophagitis companies, including Bristol Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Kyowa Hakko Kirin, Allakos, Pfizer, Revolo Biotherapeutics, EsoCap AG, NexEos Diagnostics, Inc., Celgene, among others.
Eosinophilic Gastroenteritis Market
Eosinophilic Gastroenteritis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key eosinophilic gastroenteritis companies including Allakos, AstraZeneca, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP